Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dal-GenE phase 3 trial of dalcetrapib after recent acute coronary syndrome in genetically selected patients
MOH_2017-05-08_000353Phase 3Completed
- Sponsor
- DalCor Pharmaceuticals
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) and cardiac morbidity comparing Dalcetrapib with Placebo (2 arms). Started Mar 2016; status: completed.
02
Drugs
dalcetrapib
03
Conditions
acute coronary syndrome (ACS)cardiac morbidity
Beyond the preview
Go deeper on MOH_2017-05-08_000353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-08_000353.